Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cenopodlin · CA-170

Small molecule · Antagonist of PD-L1 (CD274), PD-L2 (PDCD1LG2) and VISTA (VSIR) · developed by Curis

Phase 1 Most advanced trial (none active)

CRIS Developer

1 Registered trials

What is Cenopodlin?

Cenopodlin (CA-170) is an orally bioavailable small molecule inhibitor of immune checkpoint proteins PD-L1, PD-L2, and VISTA. It blocks PD-L1/PD-L2/VISTA-mediated suppression of T-cell responses, enhancing cytotoxic T-cell proliferation and activation against tumor cells. It is studied in advanced solid tumors and lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CA-170
Drug type: Small molecule
Targets: PD-L1 (CD274), PD-L2 (PDCD1LG2), VISTA (VSIR)
Mechanism: Antagonist of PD-L1 (CD274), PD-L2 (PDCD1LG2) and VISTA (VSIR)
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Curis, Inc. (CRIS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 646MN6KQ16

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02812875	Phase 1	Advanced Solid Tumors or Lymphomas	Completed	CRIS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors or Lymphomas

Other drugs acting on CD274 / PDCD1LG2 / VSIR

Durvalumab FDA approved Acasunlimab Phase 3 AN4005 Phase 1 AXN-2510 Phase 1 CDX-527 Phase 1 CTX-8371 Phase 1 Enristomig Phase 1 Pumitamig Phase 2/3 Vibostolimab/Pembrolizumab Phase 1/2

More from Curis

CUDC-101 Phase 1 Emavusertib Phase 1/2 Fimepinostat Phase 2 GDC-0917 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CRIS page.

Follow CRIS, the company behind Cenopodlin

See CRIS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRIS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z